Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heart-healthy NSAIDs?

This article was originally published in The Tan Sheet

Executive Summary

University of Pennsylvania researchers believe the findings of their new study suggest "the possibility of a new class of nonsteroidal anti-inflammatory drugs (NSAIDs) that steer clear of heart-disease risk and work to reduce it," according to a UPenn release. Deleting the inflammation enzyme microsomal (m)-PGE synthase (PGES)-1 gene in mice predisposed to hardening of the arteries had a "dramatic effect" on the development of atherosclerosis in male and female mice, Miao Wang, PhD, School of Medicine, UPenn, et al., found. Moreover, the deletion of mPGES-1 did not raise blood pressure or predispose the mice to thrombosis like COX-2 inhibition or deletion, the authors report in the Sept. 14 online edition of the Proceedings of the National Academy of Sciences. The PNAS study builds on a study published by the researchers earlier this year in the Journal of Clinical Investigation (1"The Tan Sheet" April 17, 2006, p. 8). The Journal of the American Medical Association released a study this week highlighting the cardiovascular risks associated with taking COX-2s...

You may also be interested in...

COX-2 Heart Risk Mechanism Suggested By Mouse Study Results

Researchers may have identified the mechanism by which COX-2 inhibitors contribute to the risk of cardiovascular events, a study published in the April Journal of Clinical Investigation finds

Vaccine Experts Inject Realism Into US Gov't's COVID-19 Timeline

The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval. 

Trump Pushes Back On OIG Report That Hospitals Want Feds To Better Police Resources, Relax Regs

When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts